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SUMMARY
The 3Rs for a good education are “reading, ’riting, and ’rithmetic.” The basis for good health care solutions for the emergent field of cell
therapy in the futurewill also involve3Rs: regulation, reimbursement, and realizationof value. Thebusinessmodels in this new fieldof cell
therapywill involve these 3Rs. This article brings forth realities facing this new industry for its approaches to provide curative health care
solutions. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–5
SIGNIFICANCE
Cell therapies (including mesenchymal stem cell-related technologies) are forecasted to substantially change disease outcomes and
thuspatient lives. Thekey to the speedof such adoptionwill be the relative success of companies tomanage thenew “3Rs”: regulation,
reimbursement, and realization of value. This new industry will progress as technology develops and clinical experience accumulates,
but only if the marketplace, regulatory and reimbursement agencies, and third-party payers enable it by fashioning supportive,
streamlined routings for getting these new therapies efficiently, and safely, to patients.
INTRODUCTION
Cell therapy involves the introduction of live cells directly from the
patient or fromanexogenous source into tissuesor thebloodstream
to affect a therapeutic outcome. The cells may be used alone (cell
therapy) or in combination with a scaffold (tissue engineering).
The technology has been in play since the mid-1950s, when hema-
topoieticbonemarrowwas first successfully transplanted to repopu-
late patients previously exposed to depopulating chemotherapy;
the first recorded bone marrow implantation took place in Ulster,
Ireland, in about 500 BC [1]. Further back in time, rudimentary cell
therapies have been used for thousands of years if one considers
aspects of animal husbandry [2]. In the 21st century, embryonic
and adult cells, both fresh and culture-expanded, allogeneic and au-
tologous, have been used in various medical circumstances [3]. The
science had progressed sufficiently so that by the 1980s and 1990s
many companies had started to produce tissue-engineered skin
substitutes ormesenchymal stem cells (MSCs) for clinical conditions
[4, 5]. Now, in the 2010s, companies are in the clinic with additional
mature and progenitor cell types (such as neural cells, retinal cells,
cardiac cells, and pancreatic cells) from a variety of sources for a
broad set of disease states. Not considered here are the businesses
that deal with hematological diseases, themanipulation of hemato-
poietic cells or their descendants, or gene therapy.
Whether the cells in question are from an autologous or alloge-
neic source, cell therapy as a clinical solution presents a business
model challenge, especially in an environment that is dominated
by large, highly successful pharmaceutical corporations that are
used to selling “blockbusters”: high-volume, low-cost goods and
high-margin off-the-shelf products. Cell therapies are far from be-
ing in the“blockbuster” space,being low-volumeandcostly toman-
ufacture, whether they are individuallymade autologous therapies
(more akin to a service) or universal allogeneic products. Now that
the science and translation of cell therapy have advanced, the busi-
nessmodel questions have extended beyond the allogeneic versus
autologous debates of the last few years to a broader set of issues
that get tohowsuchproductsareapproved, howthehealthauthor-
ities see their economic value relative to thatofother solutions, and
how companies will deliver on that value.
Thehistoric precedents for value propositioning have been set in
the biotech era of the 1980s with the emergence of Genentech,
Amgen, and Biogen, to name but a few. These new corporations
followed the business pattern established previously for small-
molecule drugs that produced major health care gains. The pro-
duction of vaccines in the 1940s and 1950s had a profound effect
in setting the business tone for the biotech companies of the 1980s.
Indeed, the failure to produce safe polio vaccines [5, 6] was one
of the primary drivers for the formation of the U.S. Food and Drug
Administration (FDA) and its current central impact on economics
and business strategies for new products for medical care delivery.
THE 3RS
In the past century, it was widely said that the basis of a good
education was the 3Rs of “reading, ’riting, and ’rithmetic.” In
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today’s world of high health care costs ($ 17% of U.S. gross do-
mestic product) and a plethora of new, exciting technologies,
the basis for good health care solutions can also be thought
of as the 3Rs: regulation, reimbursement, and realization of
value. Both public sector (especially the National Institutes of
Health) and private funding have led to the invention and devel-
opment of several medically driven sectors. Products in the de-
vice sector, such as implantable devices in orthopedics and
cardiology, have led to an increase in longevity and have solved
clinical problems of substantial scope and proportions. Corpo-
rations making such products have been allowed to fast-track
their products, oftenwithout the need for a clinical trial through
the device-specific 510(k) route. Most newmedical devices en-
ter the market via this route, which requires only demonstra-
tion of “substantial equivalence” to a previously marketed
device. For example, in this context, more than 1 million knees
and hips will be replaced with metal devices in 2014, and that
number is predicted to increase by 10%–20% per year with the
entrance of the baby boomers into the age range needing joint
replacement. However, with the emergence of cell therapy po-
tentially enabling joint tissue regeneration, this device segment
may shrink during the coming years. Given the potential of cell
therapy solutions to have long-lasting, even curative, effects
and given the inherent complexity of manufacturing and deliv-
ering such solutions to patients, paying close attention to the
3Rs will be even more important for companies trying to bring
cell therapies into the health care marketplace than it is for the
other three therapeutic pillars of health care: small-molecule
drugs, biologics, and medical devices [7].
EXEMPLAR: MSCS
The cell therapy industry is facing many unique challenges. MSCs
will be used as an exemplar for the sector as a whole to illustrate
the requirement for novel business models, as well as regulatory
and reimbursement challenges, toenable thesepotentially game-
changing therapies to deliver transformative or curative thera-
pies as part of everyday clinical practice.
MSCs reside in every tissue of the body as perivascular cells
(pericytes) and functionnaturally at sitesofbloodvessel breakage
or inflammation [8–10]. From the front of the newly released and
activated MSCs, a curtain [11] of biofactors is secreted that in-
hibits the overaggressive immune system from surveying the
damaged tissue (the first line of defense against the establish-
ment of autoimmune reactions). From the back of the MSC, tro-
phic factors [12] are secreted that inhibit ischemia-caused
apoptosis, inhibit scar formation, stimulate angiogenesis, and
stimulate the mitosis of tissue-specific progenitors. The molecu-
lar mechanisms for these activities and functions are becoming
known [13].
More than 600 clinical trials using MSCs (as shown on http://
www.clinicaltrials.gov with “mesenchymal stem cells” used as
the search term) are in progress around the world for clinical
conditions such as multiple sclerosis, amyotrophic lateral
sclerosis, stroke, acute and chronic heart failure, rheumatoid
arthritis and osteoarthritis, kidney or liver fibrosis, spinal cord
cuts or contusions, and sepsis. Thirty to forty corporations using
various formulations of MSCs or MSC-like cells from multiple
tissue sources for various clinical indications have emerged.
One of the biggest companies, Mesoblast Ltd., has a market cap-
italization of more than $1 billion and has recently purchased
the cell-therapy products and intellectual property from Osiris
Therapeutics, Inc. (the first MSC company, founded in 1992).
But in the face of challenging approval pathways and in the
wake of unexpected adverse reimbursement changes, such as
those encountered by Organogenesis and Dendreon in 2015,
a key question remains: What is the pathway to success for
the MSC products and the companies that are bringing them
and similar cell therapy technologies forward?
REGULATION
Like any small-molecule drug or biologic, a cell therapy must
satisfactorily demonstrate safety and positive therapeutic ef-
fects in preclinical animal models, after which it transitions
into human testing as a component or product to be tested in
clinical trials under the auspices of a for-profit company or, in
academia, in an investigator-initiated clinical trial. Indeed, the
first-in-humans MSC therapy was conducted at Case Western
Reserve University and University Hospitals of Cleveland in an
investigator-initiated study [14].
In either case, the standard pathway for the testing and ac-
ceptance of any new therapy in humans has been established
by the sequential stepwise process of phase I, II, and III clinical
trials. This process has its roots in the days of big pharma before
the entry of biologics; the process then adapted to accommo-
date the biologics. These same procedures and outcome mea-
sures that were established for small- and macro-molecule
drugs are now used by national regulatory agencies to assess
and approve cell therapies. But unlike drugs, whose structure,
potency, and purity can be routinely documented, cell therapies
are not so easily characterized because cells are complex multi-
component entities. This means that no standard regulatory
route is now in place that is entirely appropriate, let alone favor-
able, for cell therapy.
The current guidelines for certification of cells for therapeu-
tic use attempt tomimic aspects of the criteria long established
for drugs and, consequently, bring with them several problems
because they are not “fit for purpose.” The first problem is one
of scope. The standard phased clinical trials have been set up by
large, multibillion-dollar pharmaceutical companies that have
the resources to conduct such trials, some of which can cost
hundreds of million dollars all-in. Small companies specializing
in cell therapy do not have that wherewithal. As a conse-
quence, many clinical studies to date have been uncontrolled
and underpowered, leading to anecdotal results, unclear ben-
efits, and, often, failure in subsequent phases with larger pa-
tient populations.
Second, one can analyze and characterize a chemical or bi-
ologic drug to prove its composition, purity, and consistency
of manufacturing lot. Defining and certifying the purity and
composition of a group of living cells and ensuring that consis-
tency over time is not so easy and, in many cases, is not 100%
possible. Furthermore, in many cells, let alone mixtures of
cell populations, onemay not know exactly which components
of the cell are critical and efficacious for a specific clinical
indication.
Third, unlike a drug that is metabolized and excreted, cells
may continue to live on in the body. Therefore, the regulatory
authorities are right to be concerned about understanding
what the cells do and where they go in the body (i.e., issues
of homing, engraftment, cell division, and tumorigenicity that
2 The 3Rs of Cell Therapy
©AlphaMed Press 2016 STEM CELLS TRANSLATIONAL MEDICINE
ID: jw3b2server3dgen1 Time: 14:57 I Path: //chenas03/Cenpro/ApplicationFiles/Journals/Wiley/SCTM/Vol00601/160052/Comp/APPFile/JW-SCTM160052
18 The 3 s of Cell Therapy
Oc 2016 The Authors STE ELLS RA SLATI L E I I
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
are nonissues for conventional drug products). For some cell
types, such as MSCs, that may not live long in the body and
for which there is sufficient clinical history of safety in the clinic,
this will be less of an issue than for others. For many cell prep-
arations, however, clinical approvalmay be dependent on other
technologies, such as sophisticated in vivo tracking, which can
be problematic especially for a small, resource-constrained
company.
Not addressed here are the questions of how to “tune” thera-
peutic cells, such as MSCs, to be optimal for the disease being
treated and optimal for each patient. Currently, companies tend
to use one batch ofMSCs for all clinical situations and thus can be
expected to have high “nonresponder” rates because of the lack
of disease-specific tuning.
In short, the current regulatory process can appear long, ex-
pensive, anddisproportionately regulated, especially given that
several cell therapies appear to be transformative and in some
cases curative, but the FDA has been receptive to criteria pro-
posed by different companies and organizations with new pro-
posals for judging the efficacy and therapeutic potential of cell
therapies. One such new process, recently instituted in Japan
under their new Regenerative Medicine Act, enables a rapid
(2- to 3-year) route to conditional time-limited approval with
reimbursement. This requires an initial study to demonstrate
clear safety and, at aminimum, a suggestion of efficacy [15]. Full
approval is subject to ongoing monitoring and longer-term
studies. Such innovative regulation is essential for the field
to flourish. The first product has just emerged successfully
through this route: HeartSheet (autologous skeletal myoblast
sheets) from Terumu (Tokyo, Japan, http://www.terumo.
com), with a reimbursement price of approximately $120,000.
This and other types of new processes must be tailored to not
only the new emerging technologies but also the limited re-
sources of small corporations or academia because that iswhere
most new cell-based therapies are being developed and first
tested in humans.
In the U.S., one provision of the Regenerative Medicine
Promotion Act, introduced in March 2014, was to direct the
Department of Health and Human Services to establish a Regen-
erativeMedicine Coordinating Council, with one of its goals being
development of “consensus standards regarding scientific issues
critical to regulatory approval of regenerative medicine prod-
ucts.” In themeantime, in earlyNovember 2014, the FDA released
new draft guidelines for human cells, tissues, and cellular and
tissue-based products to clarify what constitutes “minimal ma-
nipulation” for a cell therapy.Minimalmanipulation of a cell pop-
ulation has been a key criterion for determining whether a given
cell therapy is deployed under the practice of medicine or has to
undergo the lengthier and more complex route of a traditional
biologics license application. Clarity of definition and consistency
around the world will be useful for the field because there is con-
siderable confusion among all the stakeholders. However, in Feb-
ruary 2015 the FDA started to progress the debate by issuing draft
guidelines [16].
Last, because regulatory bodies change relatively slowly in re-
sponse to the introduction of new therapies, it may be useful
for legislative bodies to take the lead in effecting regulatory
change. Certainly, the legislation brought forth in Japan has all
the world watching its progression into product approvals for
cell and gene therapies. Groups such as the Bipartisan Policy Cen-
ter in Washington are exploring ways to have the U.S. Congress
pass progressive legislation for cell-based therapy (http://www.
bipartisanpolicy.org; a conference titled “Advancing a New Policy
Framework for Regenerative Cell Therapy” was held in April
2016). If successful, new legislation will enhance the FDA’s regu-
latory capacity by settling both regulatory and societal goals. A
proposal in this regard has been made previously [17].
REIMBURSEMENT
To state the obvious, for a company to produce a health care
product on an ongoing basis, it must be paid for and the com-
pany must be able to make a profit. Although in theory the
health care system in the U.S. gives great leeway to producers
to set price and determine value of a given therapeutic, in prac-
tice it puts huge control capacity in the hands of insurance com-
panies and government agencies (especially the Centers for
Medicare & Medicaid Services) to set the monetary standards
for specific procedures and therapies. This is even more strin-
gent in countries, such as the United Kingdom, that have explicit
cost-effectiveness controls in place through bodies such as the
National Institute for Health and Care Excellence, where com-
parator based cost-effectiveness may be hard to prove for early
stage therapies.
For the foreseeable future, cell therapies will continue to be
high priced because the cost to produce the large numbers of
cells needed for a given therapy is substantial and the produc-
tion runs are relatively small, with high production costs. How-
ever, the cost-of-goods can be expected to come down for
several major reasons. First, future generations of bioprocess-
ing tools, disposables and reagents, and acquired experience
will reduce the cost of manufacturing. Second, increasing cell
potency and the development of improved targeting strategies
will lower the number of cells needed for a specific therapy, fur-
ther reducing cost and variation. Third, economies of scale will
begin to have a major impact in much the same way as has
occurred for other drug platform technologies in the past
(e.g., penicillin). Overall, this means that in the current early
stages of the cell therapy era, inefficiency must be paid for to
ensure efficacy and proof of principle for some of these treat-
ments. Once a collection of cell therapy is approved and put into
practice, the marketplace will reward companies that can do
“more for less” money. We can expect that new production
and innovative cell-delivery strategies will emerge exactly as
new strategies did in the monoclonal antibody production busi-
ness during the past 20 years.
Companies that provide therapeutic cells need to be paid for
producing and making such therapies accessible. Large pharma-
ceutical companiesmayhave the resources towait toobtain com-
pensation should marketing approval come long after initial
regulatory approval, but small companies do not have the same
luxury. Mechanisms must be found to provide payment or reim-
bursement early in the approval process, provided there are the
right contingencies regarding safety and efficacy. To date, some
cell therapies have been approved by regulatory agencies, but re-
imbursement is still lacking. Japan’snew legislation, asmentioned
earlier in this article,whichbecameeffectiveat theendofNovem-
ber 2014, is anattempt to solve this conundrum.Many companies
can be expected to take advantage of that. To date, Athersys,
Cytori Therapeutics Inc., and Mesoblast Ltd. and others have
set up shop in Japan to do so. Likewise, other governments and
national regulatory bodies are observing the impact of the
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changes in Japan. Mesoblast’s graft-versus-host product, Prochy-
mal (marketed as Temcell by JCR Pharmaceuticals Co., Hyogo, Ja-
pan, http://www.jcrpharm.co.jp)waspriced at the endof 2015by
the Japanese regulatory agency at approximately $7,000 per bag
of 72 million MSCs (about 16–24 bags are used for a complete
therapeutic course).
Another issue that will come to the fore in the cell therapy field
is that many cell therapy solutions have the promise of treating
the underlying cause of a disease. This is unlike many conven-
tional drug products that manage the disease and/or its symp-
toms. If a therapy can affect a cure or a transformative change
(e.g., a long-termhalt in diseaseprogression), how is the company
compensated for that? Currently, we pay for drugs and devices
on an interventional basis, the potentially “once-and-done” ap-
proach deployed by cell and gene therapies is therefore a new
challenge for reimbursement compared with the pay for a pill-
a-day-for-life pharmaceutical practice. The recent discussion in
the U.S. about the pricing of Sovaldi (Gilead, Foster City, CA,
http://www.gilead.com)—$1,000 a pill, $84,000 for a 3-month
regimen—brought this issue out as the debate raged as to
whether the value of avoided liver transplants was the appropri-
ate determinant. Likewise, in Europe the pricing of Glybera (uni-
Qure, Amsterdam, The Netherlands, http://www.uniqure.com/),
at $1.4 million per treatment regimen, generated controversy.
Now that human pancreatic progenitor cell therapy is starting
clinical trials, we can envision the time, for example, when b islet
cell transplants for patients with diabetes removes the need for a
lifetime of blood tests and insulin injections, not to mention
avoiding the complications of the disease and their attendant
costs. The latter are often twice the direct costs of the disease
itself. In such a case, how does a company get reimbursed appro-
priately? Should it be based on the cost of the therapeutic itself or
on the entire stream of value it creates, or somewhere in be-
tween? Recognizing that this value is created and captured only
over time has led to proposed reimbursement plans whereby a
company receives payment initially for the therapeutic interven-
tion and on a periodic basis as the therapy proves out for an indi-
vidualover time[18]. This typeofoutcomes-basedcompensation is
attractive in that it aligns economic and health interests butwill be
difficult to implement in practice because it involves assignment of
cause and effect and requires complex patient tracking and report-
ing over time, a special challenge in environments, suchas theU.S.,
without a single-payer system.
Again, for emphasis, the cost for these new therapies will be
initially high, but once the product is established in themedical
community, market pressure is sure to drive the price down.
However, it is a mistake (not to be repeated) to assume that
as more practitioners use an established cell-based therapy,
the costs per unit will decrease correspondingly. This was
not the case for skin substitutes (Organogenesis Inc. did ob-
serve some economy of scale, but not enough) and is certainly
not the case for most, if not all, cell therapies. The market will
reward innovations that allow for more efficient cell production,
tailoring cells for specific clinical situations so lower (optimal)
doses can be used and patient-specific assays (companion diag-
nostics) toensure thatproposedtreatmentsareadministeredonly
to patientswho are likely to benefit: a convergence of cell therapy
and stratified medicine. In the drug industry, it is well known that
not all patients will respond to a specific drug; in some cases, up-
wards of 30%–40% of the patients do not respond. In the case of
hyaluronan injections into osteoarthritic knees, the nonresponder
rate canbeashighas60%–70%ofpatients. Thesenewapproaches
of successful cell therapiesmust have a rapid access to themarket,
together with reimbursement, much like the newly introduced
Japanese conditional time-limited approval. In these cases,
long-term follow-up of (reimbursement) paid-for products must
be instituted.
REALIZATION OF VALUE
All companies, large and small, have investors who expect a
return on investment for both public and privately held compa-
nies. In the current marketplace, valuation of a company deliver-
ing therapeutics is an evolving process. One would think that as
companies progress fromonepositive outcome toanother at suc-
cessive trial stages (i.e., reach significant inflection points), valu-
ation would jump up, as is generally observed with small- and
macro-molecule drugs. However, this may or may not be true
depending on the market conditions and the financial indepen-
dence of each company. This is further complicated by the fact
that there are insufficient data as of yet to determinewhether cell
therapies will have the same or different success rates at the var-
ious stages of development that drugs do (for which we have de-
cades of data). For the time being, because new technologies are
so difficult to price and to project actualmarket size anddegree of
penetration, reimbursement rates and regulatory paths are in
flux, and we do not have a history of success rates in the develop-
ment path, valuations tend to underestimate true worth.
In thecell therapy industry, themostdramatic indicatorsof value
will be mergers and acquisitions, driven by both consolidation and
companies lookingtobringonnewproduct lines.Astrongdriver for
consolidation is the degree of overlap of various corporate intellec-
tual properties and the strength and weakness of the two given
companies’balancesheets.This formerconsiderationwascertainly
a strong component of why Mesoblast bought the cell therapy
portfolio from Osiris Therapeutics Inc. Now Mesoblast has two
overlapping but independently developed MSC products: their
mesenchymal precursor cells and Osiris’s MSCs. In all likelihood,
these two products will be separately pursued by Mesoblast be-
cause of the regulatory approval process. As cell therapies prove
their utility, we can expect more deals such as the Novartis invest-
ment in Gamida Cell, in which “big pharma” saw an opportunity to
enhance its product line, as well as grow the market for umbilical
cord blood transplants by making them more effective. Also, as
more clinical data become available and the field learnswhich cells
work best for which indications, we can expect to see more direct
competition as companies compare their cell-based solutions on a
head-to-head basis as happens today with drug products. That will
bring subsequent paringof product lines or cedingof selectedmar-
ket spaces as the companies “rationalize” on the basis of technol-
ogy or market position.
CONCLUSION
Cell therapies (includingMSC-related technologies) are forecasted
to substantially change disease outcomes and thus patients’ lives.
The key to the speed of such adoption will be the relative success
of companies to manage the new 3Rs (regulation, reimburse-
ment, and realization of value). This new industry will progress
as technology develops and clinical experience accumulates,
but only if themarket place, regulatory and reimbursement agen-
cies, and third-party payers enable it by fashioning supportive,
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streamlined routings for getting these new therapies efficiently,
and safely, to patients. The field should not take shortcuts, but it
should be open to questioning long-held assumptions and look
creatively for new economic and regulatory mechanisms that
can accelerate bringing these potentially transformative thera-
pies safely to patients.
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